Data reinforce dose-dependent mechanism with IMNN-001 100mg/m2 dose associated with 20% increase in IL-12 levels compared to 79mg/m2 dose Results from OVATION 2 Study continue to validate TheraPlas® ...
Historically, clinical trials have under-represented women and minorities. Clinical Trial Media's Cara Brant offers ...
The Prescription Drug User Fee Act (PDUFA) date refers to the deadline set by the US Food and Drug Administration (FDA) for reviewing a New Drug Application (NDA) or Biologics License Application (BLA ...
4h
Supernus' SPN-820 Phase 2b study in treatment-resistant depression failed to meet its primary endpoint, prompting further ...
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for ...
Exelixis’ next-generation tyrosine kinase inhibitor zanzalintinib is being tested for colorectal cancer, renal cell carcinoma ...
Broad-Spectrum Antiviral NV-387 Phase II Clinical Trial Responding to MPox Pandemic in Africa, Readying to Tackle Bird Flu ...
Cardiol Therapeutics' CardiolRx shows promise in treating heart conditions. Click here to read more about CRDL stock and why ...
Newly published detailed clinical trial data show why Exelixis abandoned a plan to seek an FDA approval for a combination of ...
The FDA granted fast track status to IBI363 for the treatment of patients with advanced squamous lung cancer after prior ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback